A Phase 1 Study to Assess Safety and Tolerability of REGN5837, an Anti-CD22 x Anti-CD28 Costimulatory Bispecific Monoclonal Antibody, in Combination With Odronextamab, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients With Aggressive B-Cell Non-Hodgkin Lymphomas (ATHENA-1)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Odronextamab (Primary) ; REGN-5837 (Primary)
Indications B-cell lymphoma; Non-Hodgkin's lymphoma
Focus Adverse reactions; First in man
Acronyms ATHENA-1
Sponsors Regeneron Pharmaceuticals

Most Recent Events

15 Jun 2023 Trial design, presented at the 28th Congress of the European Haematology Association
27 Apr 2023 Planned End Date changed from 25 Apr 2029 to 16 May 2029.
27 Apr 2023 Planned primary completion date changed from 11 May 2027 to 2 Jun 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight